ArticleJournal of hepatocellular carcinoma2025
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Early alpha-fetoprotein (AFP) response has been reported to predict the treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC). We evaluated the predictive value of another HCC tumor marker, protein induced by vitamin K absence/antagonists-II (PIVKA-II). Methods: We prospectively established a cohort of advanced HCC patients who received ICI treatment at two medical centers. Serum PIVKA-II levels were obtained before and within 4 weeks after treatment initiation. Any decline in serum PIVKA-II levels was defined as an early PIVKA-II response. Treatment response, overall survival (OS), and progression-free survival (PFS) were compared between patients with and without an early PIVKA-II response. Results: In total, 67 patients were included; liver reserve was Child-Pugh class A in all patients and albumin-bilirubin grade 1 in 67.2% of the patients. An early PIVKA-II response, which was observed in 19 (28.4%) patients, was associated with a higher objective response rate (50.0% vs 16.4%, p = 0.002). Patients with an early PIVKA-II response had superior OS (median 34.3 vs 13.7 months, p = 0.015) and PFS (median 8.4 vs 4.0 months, p = 0.049) compared with those without a response. In multivariate analysis, an early PIVKA-II response remained an independent predictor for longer OS (p = 0.012) and PFS (p = 0.044). An early PIVKA-II response can complement an early AFP response in predicting prognosis. Conclusion: An early PIVKA-II response is predictive of tumor response and superior survival outcomes in patients who received ICIs for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.